Insmed (INSM) is moving higher as traders react to fresh bullish analyst action. Morgan Stanley upgraded Insmed to Overweight from Equalweight and raised its price target to $212 from $166, pointing to higher confidence in the Brinsupri bronchiectasis launch based on recent pulmonology survey work.

The upgrade lands in the wake of Insmed’s March 23, 2026 announcement of positive topline results from the Phase 3b ENCORE study for ARIKAYCE in MAC lung disease, reinforcing expectations for a path to regulatory filing and potential label expansion. With ENCORE now public, investors are repositioning around the durability of ARIKAYCE’s franchise and how much incremental demand a broader label could unlock over time.

Near-term attention is likely to stay on two items: (1) evidence that Brinsupri’s launch traction is sustained beyond the initial ramp, and (2) concrete regulatory execution steps tied to ARIKAYCE following ENCORE (including timing and scope of filing plans). Any additional analyst target changes following ENCORE and launch checks could continue to drive outsized day-to-day moves in the stock.